A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
bioAffinity Technologies Inc shared a patient case study in which its flagship test, CyPath Lung, detected pulmonary mucinous adenocarcinoma in a high-risk individual whose previous tests and follow-up scans had suggested a low probability of cancer that could have led to diagnosis at a later, less treatable stage.
“CyPath Lung gave us the diagnostic clarity we needed to intervene before this cancer progressed further,” says Gordon Downie, MD, PhD, bioAffinity Technologies’ chief medical officer, in a release. “This patient had low PET uptake, low serum marker risk, and gaps in imaging. CyPath® Lung helped identify a relatively rare cancer that may have otherwise gone untreated.”
The female patient, now 62 years old with a history of heavy smoking and COPD, initially presented in 2022 with a suspicious left upper lobe ground-glass opacity, a hazy gray area on the CT scan that indicates increased density in the airways. The initial PET scan in 2022 showed low uptake of the radioactive tracer, which is consistent with a benign outcome, and a blood-based risk test reported a reduced malignancy risk of 11%. Serial LDCTs appeared stable through 2023, but a July 2024 scan revealed a transition to a more solid nodule, raising clinical concern.
When the patient opted against surveillance CT scans and a follow-up PET scan, her physician ordered the CyPath Lung test in March 2025. The test result of 0.56—classified as “likely malignancy”—prompted her care team to recommend surgical consultation. The patient subsequently underwent wedge resection of the upper left lung in June 2025.
Final pathology confirmed Stage 1A invasive mucinous adenocarcinoma, a lung cancer subtype that is frequently missed by standard imaging and often presents with subtle radiographic changes. The patient successfully quit smoking in March 2025.
“Once again, CyPath Lung has demonstrated that it can detect lung cancer at Stage 1A when traditional diagnostic tests indicated a low probability of cancer. For high-risk patients with inconclusive imaging or limited diagnostic options, we believe that our noninvasive test can offer a vital path forward,” says Maria Zannes, president and CEO of bioAffinity Technologies, in a release.
ID 194809772 © Axel Kock | Dreamstime.com
